Company profile for Adverum Biotechnologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and c...
Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
800 Saginaw Drive, Redwood City, CA 94063
Telephone
Telephone
650-656-9323
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196864/32452/en/Adverum-Reminds-Stockholders-to-Tender-their-Shares-into-the-Offer-by-Lilly.html

GLOBENEWSWIRE
01 Dec 2025

https://www.reuters.com/legal/transactional/eli-lilly-buy-gene-therapy-developer-adverum-about-262-million-deal-2025-10-24/

REUTERS
25 Oct 2025

https://www.globenewswire.com/news-release/2025/09/22/3153890/32452/en/Adverum-Biotechnologies-Announces-Completion-of-Screening-for-Pivotal-Phase-3-ARTEMIS-Trial-of-Ixo-vec-for-Wet-Age-Related-Macular-Degeneration.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/09/05/3145476/32452/en/Adverum-Biotechnologies-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
05 Sep 2025

https://www.globenewswire.com/news-release/2025/08/12/3131551/32452/en/Adverum-Biotechnologies-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Pipeline-Highlights.html

GLOBENEWSWIRE
12 Aug 2025

https://www.globenewswire.com/news-release/2025/08/06/3128630/32452/en/Adverum-Biotechnologies-to-Participate-in-the-H-C-Wainwright-5th-Annual-Ophthalmology-Virtual-Conference.html

GLOBENEWSWIRE
06 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty